drugset / Trial / NCT06641557
A Phase I Dosing Study of IkT-148009.
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 study in older adult or elderly healthy volunteer subjects to measure the safety, tolerability and pharmacokinetic (PK) profile of IkT-148009 capsules given as multiple capsules.
Timeline
- Start
- 2023-02-21
- Primary completion
- 2023-03-21
- Completion
- 2023-04-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RISVODETINIB | Small molecule | 200 mg | — |
Indications
No indication recorded.